5-year efficacy of entecavir in Indian patients with chronic hepatitis B

Ray, Gautam

doi:10.1007/s12664-016-0664-x

Cited by 7 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the literature, the discussed adverse reactions were mostly well tolerated. In this study, the adverse reactions in the TDF and ETV groups were considered mild and suitable for the long-term oral treatment of CHB[22, 23].…”

Section: Discussionmentioning

confidence: 99%

Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

ObjectiveTo compare the efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B.MethodsThe Web of Science, PubMed, Cochrane Library, EMBASE, Clinical Trials and China National Knowledge Infrastructure(CNKI) databases were electronically searched to collect randomized controlled trials (RCTs) regarding the comparison between tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B (CHB) since the date of database inception to July 2019. Two researchers independently screened and evaluated the obtained studies and extracted the outcome indexes. RevMan 5.3 software was used for the meta-analysis.ResultsEarly on, tenofovir had a greater ability to inhibit the hepatitis B virus, I2 = 0% [RR = 1.08, 95% CI (1.03, 1.13), P<0.01] (96 weeks). Entecavir can normalize the ALT levels earlier, I2 = 0% [RR = 0.87, 95% CI (0.77, 0.98), P = 0.02] (48 weeks). However, there was no statistically significant difference between TDF and ETV at 144 weeks. Tenofovir was as effective as entecavir in terms of HBeAg clearance and HBeAg seroconversion, I2 = 0% [RR = 1.05, 95% CI (0.68, 1.62), P = 0.82]; I2 = 69% [RR = 0.93, 95% CI (0.54, 1.61), P = 0.80]. The difference in the incidence of elevated creatine kinase levels was not statistically significant I2 = 0% [RR = 0.66, 95% CI (0.27, 1.60), P = 0.35].ConclusionsTenofovir and entecavir were equally effective in the treatment of patients with nucleos(t)ide analogue-naive chronic hepatitis B. In addition, TDF has an advantage in the incidence of hepatocellular carcinoma. Additional RCTs and a large-sample prospective cohort study should be performed.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Elovac-B & Vaxtar-5™ (Indian Immunologicals Limited, India) Entecavir (Schwitz Biotech), Tenofovir (Gilead Sciences, Inc.), Lamivudine (Anant Pharmaceuticals Pvt. Ltd.), Adefovir and Telbivudine (Novartis India Ltd) Worldwide Humans [ [61] , [62] , [63] , [64] ] Influenza (Influenza virus) Respiratory droplets May 16, 2009 from Telengana (Hyderabad) Quadrivalent (Lupin Laboratories Ltd., CSL Seqirus, Sanofi Pasteur Inc) Vaxigrip (Chiron Panacea Vaccines Pvt.Ltd. ), Vaxigrip (Sanofi Pasteur), Fiuarix (Glaxo Smith Kline Pharmaceuticals Ltd), Influgen (Lupin Laboratories Ltd.), and Influvac (Abbott) Oseltamivir (Hetero Drugs Ltd. and Ranbaxy Laboratories), Zanamivir (GlaxoSmithKline), Peramivir (Biocryst Pharmaceuticals) North and South America, Europe, and parts of Asia, Africa Pigs, wild birds [ 70 , 71 ] Acute Respiratory Illness (MERS-CoV, SARS-CoV) Respiratory droplets or hand-to-hand contact Kerala, on January 27, 2020 COVAXIN® (Bharat Biotech) COVOVAX®, Covishield® (Serum Institute of India Pvt.…”

Section: Emerging Disease and Its Vaccinementioning

confidence: 99%

“…Some drugs are manufactured by Indian pharmacy industry, including Entecavir (Schwitz Biotech), Tenofovir (Gilead Sciences, Inc.), Lamivudine (Anant Pharmaceuticals Pvt. Ltd.), Adefovir and Telbivudine (Novartis India Ltd.) [ 63 , 64 ].…”

Section: Emerging Disease and Its Vaccinementioning

confidence: 99%

Human health implications of emerging diseases and the current situation in India's vaccine industry

Behera,

Mishra,

Jena

et al. 2023

Science in One Health

View full text Add to dashboard Cite

“…This difference, however, did not persist in the long term and in patients with HBV-related cirrhosis [22]. Both ETV and TDF have been clinically proven to be effective in the long term for the treatment of patients with chronic HBV infection, including those who relapsed after PegIFNa therapy [23][24][25][26]. Further, ETV has also been found to be effective in patients with chronic kidney disease, including those on hemodialysis, without affecting the renal function [27].…”

Section: Treatment Of Chronic Hbv Infection: Current Guideline Recommendationsmentioning

confidence: 99%

An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia

Charlton

Alam²,

Shukla

et al. 2020

J Gastroenterol

View full text Add to dashboard Cite

Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV) infection. The use of guideline-recommended nucleos(t)ide analogs with high barrier to resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), is one of the key interventions for curbing HBV infection and associated morbidity in Asia. However, there are some challenges to the use of ETV and TDF; while ETV is associated with high resistance in lamivudine (LAM)-exposed (especially LAM-refractory) patients; bone and renal safety issues are a major concern with TDF. Hence, a panel of twenty-eight expert hepatologists from Asia convened, reviewed the literature, and developed the current expert opinion-based review article for the use of TAF in the resource-constrained settings in Asia. This article provides a comprehensive review of two large, phase 3, double-blind, randomized controlled trials of TAF versus TDF in HBeAg-negative (study 0108) and HBeAg-positive (study 0110) chronic HBV patients (> 70% Asians). These studies revealed as follows: (1) non-inferiority for the proportion of patients who had HBV DNA < 29 IU/mL; (2) significantly high rate of normalization of alanine aminotransferase levels; (3) no incidence of resistance; and (4) significantly better bone and renal safety, with TAF vs. TDF up to 144 weeks. Considering the benefits of TAF, the expert panel proposed recommendations for optimizing the use of TAF in Asia, along with guidance on specific patient groups at risk of renal or bone disease suitable for TAF therapy. The guidance provided in this article may help clinicians optimize the use of TAF in Asia.

show abstract

5-year efficacy of entecavir in Indian patients with chronic hepatitis B

Abstract: Entecavir will need to be continued indefinitely in Indian patients with CHB.

Cited by 7 publications

References 18 publications

Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis

Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis

Human health implications of emerging diseases and the current situation in India's vaccine industry

An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia

Contact Info

Product

Resources

About